A new dawn in
the treatment of
weight loss

LIR life Sciences is engaged in the research, development and commercialization of products intended to address weight loss and longevity through novel polypills and new mechanisms of delivery of these therapies. We intend to make these treatments accessible to everyone for a fraction of the high costs currently in place by drugs like Ozempic and Mounjaro.

Market Access, Innovation and Scale.

Revolutionizing obesity treatment with novel delivery systems.

Lir Life Sciences aims to develop a transdermal delivery system uniquely delivers blockbuster drug GLP-1, potentially offering a novel approach to obesity treatment that aims to improve patient compliance and minimizes side effects.
Propietary IP

Applying for international IP patent for advanced synthesis andtransdermal technology, securing a competitive edge andsupporting sustainable growth.

Market Potenial

The obesity treatment market is rapidly expanding, projected togrow from $8 billion in 2023 to approximately $100 billion by2030 as reported by Goldman Sachs.

Leadership Team

Lir Life Sciences is led by a team of experienced professionalswith deep expertise in pharmaceuticals, clinical research, andbusiness management, venture capital and capital marketsensuring strong execution of business strategies.

The future of GLP1 treatment is here.

Contact Us

info@lirlifesciences.com

Copyright © Lir Life Sciences